Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.

R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark)

Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark). Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.. 1603

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012


Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 674s
Year: 2007

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial
Source: ERJ Open Res, 6 (4) 00534-2020; 10.1183/23120541.00534-2020
Year: 2020



A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection
Source: Virtual Congress 2020 – Chinese programme 2020: Part I
Year: 2020


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013


Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases
Year: 2007


Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study
Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD
Year: 2008


Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013

Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming
Source: Eur Respir J 2003; 22: Suppl. 45, 388s
Year: 2003

A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

Tocilizumab treatment for patients with Covid-19 pneumonia - a single centre observational study
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021